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Objectives: To describe the use of second-line protease-inhibitor regimens in Me ´de-
cins Sans Frontie `res HIV programmes, and determine switch rates, clinical outcomes,
and factors associated with survival.
Design/Methods: We used patient data from 62 Me ´decins Sans Frontie `res programmes
and included all antiretroviral therapy-naive adults (>15 years) at the start of anti-
retroviral therapy and switched to a protease inhibitor-containing regimen with at least
one nucleoside reverse transcriptase inhibitor change after more than 6 months of
nonnucleoside reverse transcriptase inhibitor ﬁrst-line use. Cumulative switch rates and
survival curves were estimated using Kaplan–Meier methods, and mortality predictors
were investigated using Poisson regression.
Results: Of 48338 adults followed on antiretroviral therapy, 370 switched to a second-
line regimen after a median of 20 months (switch rate 4.8/1000 person-years). Median
CD4 cell count at switch was 99cells/ml (interquartile ratio 39–200; n¼244). A
lopinavir/ritonavir-based regimen was given to 51% of patients and nelﬁnavir-based
regimen to 43%; 29% changed one nucleoside reverse transcriptase inhibitor and 71%
changed two nucleoside reverse transcriptase inhibitors. Median follow-up on second-
line antiretroviral therapy was 8 months, and probability of remaining in care at 12
months was 0.86. Median CD4 gains were 90 at 6 months and 135 at 12 months. Death
rates were higher in patients in World Health Organization stage 4 at antiretroviral
therapy initiation and in those with CD4 nadir count less than 50cells/ml.
Conclusion: The rate of switch to second-line treatment in antiretroviral therapy-naive
adults on non-nucleoside reverse transcriptase inhibitor-based ﬁrst-line antiretroviral
therapy was relatively low, with good early outcomes observed in protease inhibitor-
based second-lineregimens. Severeimmunosuppression wasassociated with increased
mortality on second-line treatment.
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AIDS 2008, 22:1305–1312
Keywords: Africa, antiretroviral therapy, low-income population, resource-
limited setting, reverse transcriptase inhibitors, second line, viral load
Introduction
Since 2001, Me ´decins Sans Frontie `res (MSF) has provided
antiretroviral therapy (ART) to more than 100000 people
in resource-limited settings (RLS), using World Health
Organization (WHO)-recommended ﬁrst-line regimens
involving two nucleoside reverse transcriptase inhibitor
(NRTI) and one non-nucleoside reverse transcriptase
inhibitor(NNRTI)antiretroviraldrugs.Satisfactoryshort-
term outcomes in such settings have been described by
MSF and others [1–4], and this contributed to the rapid
scalingupofART.AsaccesstoandtimeonARTincreases,
the need for second-line regimens in RLS becomes a
priority due to the development of drug resistance [5,6].
Clinicalprogrammedataareurgentlyneededtohelpdesign
longer-term treatment strategies, and to allow programme
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managers, governments, donors, and pharmaceutical
manufacturers to more accurately forecast antiretroviral
drug ﬁrst-line and second-line requirements [7].
Detection of ﬁrst-line ART failure in most RLS relies on
immunological or clinical criteria, as routine viral load
monitoring isfrequently notavailableduetoﬁnancialand
technical constraints. Thus, diagnosis of failure is often
delayed [8], and might favour not only clinical disease
progression [9], but also development of antiretroviral
resistance due to concurrent antiretroviral drug exposure
and high viral replication. The appearance of resistance
mutations [e.g. thymidine analogue mutations (TAMs)]
may thus jeopardize the effectiveness of second-line ART
regimens in settings where few treatment options are
available [10]. Additional constraints regarding second-
line ART in RLS include availability of less robust
second-line ART regimens (e.g., nonboosted protease
inhibitors); difﬁculty in ensuring long-term adherence
due to increased pill burden or meal restrictions; and high
price of drugs (up to ten times more expensive than ﬁrst-
line regimens) [11]. Therefore, concerns about the
effectiveness of second-line ART in RLS have been
raised, but few data on this exist [12,13].
We report here the rate of switch from ﬁrst-line to
second-line ART in MSF programmes; survival and
clinico-immunological outcomes of patients on second-




We used routinely collected individual patient data
(FUCHIA software, Epicentre, Paris) from 62 MSF-
supported HIV programmes in 26 countries between
October 2001 and December 2006. Data collected
included sex; age; treatment history; ART prescription
date and regimen; dates of visit, appointment, or death;
WHO clinical stage; and CD4 cell count and viral load,
when available.
All programmes provided free care, including antire-
troviral drugs and laboratory investigations, with clinical
consultation performed by doctors, clinical ofﬁcers, or
nurses. Eligibility criteria for ART were based on the
2003 WHO recommendations [14] and generic anti-
retroviral drugs used, mainly in the form of NNRTI-
containingﬁxed-dosecombinations. Adherence counsel-
ing was provided to all patients both prior to and during
ART. Programmes routinely provided prophylaxis and
treatment of opportunistic infections and often nutri-
tional support for malnourished individuals. CD4 cell
counts were measured using either automated or manual
methods (Partec, Dynabeads, Beckton Dickinson).
Although virological monitoring was not routinely
performed, viral load was occasionally determined when
clinicians suspected treatment failure and adequate
laboratory facilities were available.
Study population
WeanalysedinformationfromallART-naiveadults (>15
years) at MSF programme inclusion and who received an
NNRTIﬁrst-lineregimenformorethan6months.Missing
agedatawastheonlyreasonforexclusionfromthisstudy.To
exclude antiretroviral drug substitutions for toxicity, we
deﬁnedsecond-linetherapyasaconcomitantinitiationofa
protease inhibitor-containing regimen and a change in at
leastoneNRTIdruginpatientswhohadreceivedNNRTI
ﬁrst-linetherapyformorethan6months.Womenwhohad
received prevention of mother-to-child transmission
(PMTCT) prophylaxis were considered naive. Reasons
for switch to second line were not prospectively collected.
Treatment failure was deﬁned as CD4 at switch less than
CD4cellcountatARTinitiation;CD4cellcountatswitch
less than 100 cells; new WHO stage 3 or 4 event within
3 months before switch; and/or viral load more than
1000copies/ml, when available [15].
Statistical analyses
We estimated the probabilities of remaining on ﬁrst-line
ART,rateofswitchtosecond-lineART,andprobabilities
of remaining alive and in care after ﬁrst-line and second-
line therapy initiation using Kaplan–Meier and censor-
ing-naive methods. For patients on ART for more than
19.8 months (the median time of follow-up on ART
before the switch to second line), we compared the
probabilities of remaining alive and in care in patients
started or not on second-line therapy with the log-rank
test. We then described patient characteristics at the start
of ARTand at switch, and BMI and CD4 gains at 6, 12,
and 24 months after switch, using medians, interquartile
ranges (IQR), and percentages, as appropriate. Finally, we
investigated factors associated with death or lost to
follow-up (LFU; a missed appointment for >2 months)
using Poisson regression. To control for the heterogeneity
of the data, as information from several projects was
included (and access to CD4 testing and/or to diagnostic
facilities for opportunistic infections vary in different
contexts), all the models were adjusted for geography
(sub-Saharan Africa, Asia, and Latin America) and for
factors signiﬁcantlyassociated with theoutcomes (P value
from likelihood ratio tests <0.05).
Results
Description of the global Me ´decins Sans
Frontie `res cohort
Afterexcluding856(1.7%)patientswithunknownage,we
analysed data from 48338 naive adults on ART for more
than 6 months, 78% treated in MSF-supported projects in
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Africa, 18% in Asia, 4% in Latin America, and 0.2% in
Eastern Europe (Table 1). At the start of ART, patient
median age was 35 years (IQR 30–42), and 62% were
women. The median CD4 cell count was 110cells/ml
(IQR 46–178; n¼34799), and 84% were classiﬁed as
WHO clinical stage 3 or 4. The ﬁrst-line ART regimen
most frequently prescribed was stavudine/lamivudine/
nelﬁnavir(d4T/3TC/NVP)(86%),andmediandurationof
ART was 18 months (IQR 11–25), with 13871 (29%)
patientsontreatmentfor morethan2years.Forpatientson
regularfollow-up,theprobabilityofremainingonﬁrst-line
ARTafter 36 months was 0.98 (95% CI 0.97–0.98). The
probability of remaining alive and in care at 24 months
was 0.87.
Description of patients on second-line
antiretroviral therapy
A total of 370 (0.8%) patients began a second-line
regimen after a median of 20 months (IQR 14–27),
corresponding to a switch rate from ﬁrst to second line of
4.8/1000 person-years (95% CI 4.3–5.3) (Fig. 1) (Table
2). Switch rates ranged from 4.2/1000 person-years in
sub-Saharan projects to 6.5/1000 in Asia, 7.4/1000 in
Latin America, and 14.5/1000 in Eastern Europe. At
the start of ﬁrst-line ART, 334 (90%) patients were
in cumulative WHO clinical stage 3 or 4, and had a
median BMI of 20kg/m
2 (IQR 18–22; n¼321) and
median CD4 cell count of 52cells/ml (IQR 18–131;
n¼304). Median CD4 nadir was 39cells/ml (IQR 13–
86; n¼368).
At the time of switch, median CD4 cell count was
99cells/ml (IQR 39–200; n¼244), 32% having less than
50cells/ml, 50% had less than 100cells/ml, and 75%
had less than 200cells/ml. Median viral load was
43188copies/ml (IQR 16406–166197; n¼75), and
median BMI was 21kg/m
2 (IQR 19–24; n¼320) with
45 (14%) patients having less than 17kg/m
2.
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Table 1. Demographic and clinico-immunological characteristics of patients treatment-naı ¨ve at the start of antiretroviral treatment (ART),
Me ´decins Sans Frontie `res (MSF) HIV cohort 2001–2006, 26 countries.
Patient characteristics All MSF ART patients (n¼48338) Second-line patients (n¼370)
Women (%) 29794 (61.7) 217 (58.7)
Median age [IQR] (years) 35.0 [29.6–41.6] 35.1 [29.3–40.8]
Continent (%)
Sub-Saharan Africa 37918 (78.4) 250 (67.6)
Asia 8459 (17.5) 93 (25.1)
Latin America 1864 (3.9) 25 (6.8)
Eastern Europe 97 (0.2) 2 (0.5)
Median months of follow-up on ART [IQR]
Before switch
a 17.5 [11.2–25.4] 19.8 [13.9–27.3]
After switch 7.8 [2.4–18.4]
Median CD4 nadir [IQR] (cells/ml) 117 [51–187], n¼45319 39 [13–86], n¼368
Characteristics at the start of ART
Cumulative WHO stage at ART start (%)
Stage 3 27353 (56.6) 208 (56.2)
Stage 4 13067 (27.0) 126 (34.1)
Median BMI [IQR] (kg/m
2) 19.7 [17.8–21.9], n¼37780 20.1 [18.1–22.1], n¼321
Median CD4 cell count [IQR] (cells/ml) 110 [46–178], n¼34799 52 [18–131], n¼304
ART regimen (%)
3TC-d4T-NVP 41557 (86.0) 265 (71.6)
3TC-d4T-EFV 4167 (8.6) 45 (12.2)
3TC-ZDV-NVP 1292 (2.7) 33 (8.9)
Other 1322 (2.7) 27 (7.3)
Characteristics at switch
Median CD4 cell count [IQR] (cells/ml) – 99 [39–200], n¼244
Median VL [IQR] (copies/ml) – 43188 [16406–166197], n¼75
Second-line regimen (%)
Type of PI –
LPV based – 188 (50.8)
NFV based – 160 (43.2)
Other – 22 (5.9)
Boosted PI – 207 (56.0)
NRTI class –
ZDVþddI – 125 (33.8)
ABCþddI – 80 (21.6)
TDF based – 56 (15.1)
ZDVþ3TC only – 44 (11.9)
Other ddI based – 50 (13.5)
Other – 15 (4.1)
IQR are shown in square brackets and percentages in brackets. ABC, abacavir; BMI, body mass index; ddI, didanosine; EFV, efavirenz; d4T,
stavudine; IQR, interquartilerange; LPV, lopinavir; NFV,nelﬁnavir;NRTI, nucleosidereverse transcriptase inhibitor;NVP, nevirapine;PI, protease
inhibitor; TDF, tenofovir; 3TC, lamivudine; VL, viral load; ZDV, zidovudine.
aMedian months on ART (ﬁrst line or second line).Copyright © Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited.
During the 3 months before the switch, a new WHO
clinical stage 3 or 4 condition had been recorded for 111
(30%) patients and a CD4 value of less than or equal to
CD4 cell count at the start of ART for 69 (34%). Among
patientswhowere switched tosecondline,230 (62%)had
atleastoneofthecriteriaoftreatmentfailureaccordingto
the 2006 WHO criteria. A total of 139 patients had no
CD4 data collected and thus could not be evaluated with
regard to immunological treatment failure criteria.
The protease inhibitor component of the second-line
regimen was lopinavir/ritonavir (LPV/r) for 188 (51%)
patients and nelﬁnavir (NFV) for 160 (43%); 56%
received a boosted protease inhibitor. The most
frequently administered NRTI combinations were
zidovudine-didanosine (ZDV-ddI; 34%) and abacavir
(ABC)-ddI (22%). Only one NRTI drug had been
changed instead of two for 115 (31%) patients, and only
12% received ZDV-lamivudine (ZDV-3TC) in combi-
nation with a protease inhibitor.
Second-line treatment outcomes
Median follow-up on second-line ART was 8 months
(IQR 2–18), with 138 (37%) patients on treatment for
more than 12 months. Twenty-eight (8%) patients died
after a median of 5 months (IQR 3–8), and 18 (5%) were
LFU after a median of 9 months (IQR 3–14). Recorded
causes of death were Kaposi sarcoma (n¼7), tuberculosis
(n¼4), wasting syndrome (n¼3), and one suspicion of
cerebral mass. The probabilities of remaining alive and in
care at 12 and 24 months were 0.86 (95% CI: 0.81–0.90)
and 0.77 (95% CI: 0.69–0.83), respectively
(Fig. 2a)(Table 3). These ﬁgures did not differ by the
number of NRTI drugs changed (P¼0.99) and were
slightly, but not signiﬁcantly, higher for patients on
LPV/r-second-line therapy (unadjusted P¼0.06, com-
pared with NFV-based therapy). The probability of
remaining alive and in-care for patients with a follow-
up of at least 19.8 months was similar in patients switched
and not switched to second-line therapy at 20 months of
ART, butitwaslower for patientsonsecond lineafter that
(log-ranktestPvalue0.03;Fig.2bandTable4).However,
latter estimates were based on data from few patients.
Median CD4 cell count was 184cells/ml (IQR 128–306;
n¼106) and 247cells/ml (IQR 132–302; n¼78) at 6
and12months,respectively.MedianCD4increasewas90
(37–141; n¼73) and 135 (50–198; n¼55) at 6 and
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Fig. 1. Cumulative switch rates from ﬁrst-line to second-line
antiretroviral treatment (ART) and 95%conﬁdence intervals
among naı ¨ve patients at the start of ART, Me ´decins Sans
Frontie `res HIV cohort 2001–2006, 26 countries.
Table 2. Number of patients, cumulative person-years of follow-up
and cumulative incidence of switches to second-line therapy,
Me ´decins Sans Frontie `res, HIV cohort 2001–2006, 26 countries.
Time (months) 12 24 36 48 60
Number of patients 34630 13771 3202 434 29
Cumulative
Person-years 44696 68179 75694 77120 77272
Switches to second-
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Fig. 2. Probabilities of remaining in care, Me ´decins Sans Frontie `res, HIV cohort 2001–2006, 26 countries. (a) Kaplan–Meier
estimates of remaining in care after switch from ﬁrst-line to second-line treatment in antiretroviral treatment (ART)-naive patients.
(b)Kaplan–MeierestimatesofremainingincareafterthestartofARTinART-naivepatientsforpatientsswitchedornotswitchedto
second-line ART with a follow-up on ART of at least 19.8 months.Copyright © Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited.
12months,respectively(Fig.3).Oneyearafter switch,six
(10.9%) patients had a CD4 cell count of less than
50cells/ml, 14 (25.5%) had less than 100cells/ml, and 30
(54.5%) had less than 200cells/ml. Furthermore, median
weight gains at 6 and 12 months after switch were 0.5kg
(IQR 2to3;n¼205)and1kg(IQR  2to4;n¼139),
respectively. Onlyeight (6%; n¼127) patients had a BMI
of less than 17kg/m
2 1 year after the switch. After 6
months of treatment, 46 (12.4%) patients developed a
WHO condition stage 3 or 4 (14 at stage 4 condition),
and the CD4 cell count was equal or below the value
recorded at switch for 11% (8/75).
Antiretroviral drug-relatedtoxicity leading to cessationor
change of the antiretroviral drug regimen was recorded
for only three (1%) patients: two on ZDV-ddI-NFV
(neuropathy WHO grades 1 to 2 and lactic acidosis) and
one on ZDV-ddI-IDV/r (hepatoxicity grade 4).
Factors associated with death and lost to
follow-up
In multivariable analyses, death and LFU rates were
higher in patients classiﬁed as WHO stage 4 at ﬁrst-line
ART initiation [incidence rate ratio (IRR) 2.35, 95% CI
1.29–4.31; P¼0.006], and in those with CD4 cell count
nadir less than 50cells/ml (IRR 1.73, 95% CI 0.91–3.29;
P¼0.09) (Table 5). Interestingly, the number of NRTI
drugs changed (P¼0.39), level of CD4 cell count at
switch (P¼0.26), and type of protease inhibitor (boosted
versus nonboosted; P¼0.31) were not signiﬁcant
predictors of survival in this analysis.
Discussion
In this ﬁrst published study of second-line ART in RLS,
we have shown encouraging early treatment outcomes,
with clinical and immunological outcomes similar to
those published for ﬁrst-line regimens in RLS [1,3,16].
Nine out of ten patients were still alive after 12 months of
treatment, and few patients were diagnosed with new
severe AIDS-related illnesses. However, over half of the
patients were still at a signiﬁcant risk of life-threatening
opportunistic infections (CD4 <200cells/ml) after
12 months of treatment, showing that room for
improvement exists even for second-line therapy.
We found that overall a relatively small proportion of
patients, after at least 6 months on ART in MSF
programmes, switched to a second-line regimen for
treatment failure (switch rate 4.8/1000 person-years; 6%
of cohort at 48 months). Switch rates to second-line
therapy were lowest in sub-Saharan patients and highest
in Eastern Europeans, probably reﬂecting differences in
access to viral load and CD4 testing in those contexts
(many MSF projects in Africa are based in rural areas).
Our observed switch rate probably reﬂects only the most
obvious cases of treatment failure, due to our inability to
accurately diagnose when a ﬁrst-line regimen should be
changed to second line. This is also suggested by our
ﬁnding of lower survival in patients switched to second-
linetherapycomparedwiththosewhodidnot,suggesting
that late diagnosis of failure would increase the risk of
death in patients started on second-line ART. In the
absence of routine virological monitoring in our
programmes, diagnosis of failure is usually based on
either the occurrence of a clinical event, or on
immunological criteria as per WHO guidelines [14].
These data from a large number of RLS highlight the
increased need for second-line therapy in similar settings.
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Table 3. Number of patients and incidence of deaths or lost to
follow-up, Me ´decins Sans Frontie `res, HIV cohort 2001–2006,
26 countries.
Time (months) 6 12 18 24
Patients at risk 209 144 95 38
Deaths or lost to follow-up 14 4 7 10
Table 4. Number of patients and incidence of deaths or lost to
follow-up by switch status, Me ´decins Sans Frontie `res, HIV cohort
2001–2006, 26 countries.
Time (months) 24 36 48
Not switched to second-line ART
Patients at risk 13633 3172 430
Deaths or lost to follow-up 372 403 47
Switched to second-line ART
Patients at risk 281 140 26
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Fig. 3. Immunological response on second-line antiretro-
viral treatment (ART), Me ´decins Sans Frontie `res HIV cohort
2001–2006, 26 countries. Bars denote number of patients
(primary Y axis). Line graph denotes CD4 cell count
(secondary Y axis).Copyright © Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited.
Evidence of the efﬁcacy of rescue regimens has been
shown in studies conducted in resource-rich settings,
where median CD4 cell count at second-line initiation is
higher, viral load monitoring routinely performed, and
treatment options readily available. In a European study
[17] conducted before the widespread availability of
genotyping, patients initiating a second protease inhibitor
regimen at lower viral load with higher CD4 cell counts,
or receiving additional nucleosides, were more likely to
achieve undetectable viral loads. Studies in South Africa
[18,19], where viral load is routinely measured and
treatment failure is deﬁned as two consecutive viral load
measurements more than 5000copies/ml, reported that
after36monthsofNNRTI-basedﬁrst-linetherapy,5.6to
11.9% of patients switched to a second-line regimen.
Althoughthenumberofinitiallynaivepatientsswitchedto
second line in our study was small, in RLS there is an
increasing need for second-line ART regimens as ART
cohorts mature and access to virological monitoring
increases [20]. Detection of early treatment failure will
ensure that patients are able to switch regimens before the
occurrence of severe clinical events and will prevent
unnecessary early switches. One major strategy for
improving the diagnosis of ﬁrst-line treatment failure in
RLS is to increase viral load monitoring. In the absence of
regularviralloadmonitoring,diagnosisoftreatmentfailure
might be delayed due to reliance on less sensitive
immunological or clinical methods [8]. Although not a
RLS, our ART programme in Khayelitsha, South Africa,
routinely measures patient viral load (and CD4 cell count)
atbaselineand3and6monthsafterthestartoftreatment,as
well as every 6 months thereafter [18]. As costs and
technological limitations decrease for viral load testing
[21],itsuseinRLScouldbeneﬁciallyincreaseswitchingto
second-linetherapywhileoptimizingthedurationofﬁrst-
line regimens. Ideally, treatment-failure algorithms [22]
could be designed based on diagnostic parameters, such as
viral load, CD4 cell count, or haemoglobin levels, and
incorporated into HIV treatment guidelines in the ﬁeld.
In RLS, constraints at the treatment level also negatively
affect therapy outcomes. Even in the presence of
virological failure, clinicians working in RLS may be
reluctant to change to second-line regimens, as shown in
one of the before-mentioned South African studies [19].
Evidence shows that clinical and immunological beneﬁts
can be obtained on avirologically failing regimen, but this
effect hasbeen demonstratedonlyinpatientsona protease
inhibitor-based regimen [23]. Prices of second-line drugs
havebeenreportedtobeaboutten timeshigher thanﬁrst-
line agents [24]. Also, concerns exist about the limited
efﬁcacy of available second-line regimens involving
boostedandnonboostedproteaseinhibitorsortheaddition
of a single new NRTI. Clinicians often also doubt the
immediate beneﬁt of second-line therapy because of the
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Table 5. Factors and incidence of death or lost to follow-up of patients achieving early immunological success on second-line antiretroviral
treatment (ART), Me ´decins Sans Frontie `res HIV cohort 2001–2006, 26 countries.
Patients characteristics
Lost to follow-up or death
n (N¼45) Person-years Rate/100 (95% CI) IRR (95% CI) IRRa (95% CI)
Sex
Men 23 132 17.46 (11.60–26.27) 1, P¼0.09 1, P¼0. 50
Women 22 202 10.90 (7.18–16.55) 0.59 (0.32–1.07) 0.81 (0.43–1.52)
Age group
>35 years 19 180 10.58 (6.75–16.59) 1, P¼0.09 1, P¼0.11
 35 years 26 154 16.88 (11.49–24.78) 1.69 (0.92–3.08) 1.62 (0.89–2.97)
BMI group at ART start
 17kg/m
2 28 240 11.68 (8.06–16.91) 1, P¼0.46 1, P¼0.12
<17kg/m
2 5 60 8.32 (3.46–19.99) 0.71 (0.27–1.83) 0.49 (0.19–1.30)
WHO stage 4 at ART start
No 22 224 9.81 (6.46–14.90) 1, P¼0.003 1, P¼0.006
Yes 23 109 21.03 (13.98–31.65) 2.53 (1.39–4.60) 2.35 (1.29–4.31)
CD4 cell count nadir
 50cells/ml 15 159 9.41 (5.67–15.61) 1, P¼0.04 1, P¼0.09
<50cells/ml 29 173 16.74 (11.63–24.09) 1.93 (1.03–3.65) 1.73 (0.91–3.29)
CD4 cell count at switch
 50cells/ml 14 161 8.72 (5.16–14.72) 1, P¼0.08 1, P¼0.26
<50cells/ml 12 58 20.72 (11.77–36.48) 2.35 (1.08–5.09) 1.86 (0.77–4.46)
Second-line regimen
Number of changes in NRTI component
One 15 107 14.06 (8.48–23.32) 1, P¼0.56 1, P¼0.39
Two 30 227 13.22 (9.24–18.91) 0.83 (0.44–1.56) 0.75 (0.39–1.43)
Use of boosted PI
Yes 31 201 15.45 (10.87–21.97) 1, P¼0.36 1, P¼0.31
No 14 133 10.53 (6.24–17.78) 0.67 (0.27–1.65) 0.63 (0.25–1.59)
CI, conﬁdence interval; IRR, incidence rate ratio from Poisson regression adjusted for geography (sub-Saharan Africa, Asia, Latin America); IRRa,
incidence rate ratio from Poisson regression adjusted for geography, CD4 nadir counts, and WHO stage 4 at ART start; NRTI, nucleoside reverse
transcriptase inhibitor; PI, protease inhibitor. P value from likelihood ratio test.Copyright © Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited.
difﬁculties in ensuring patient treatment adherence due to
the high pill burden of protease inhibitor-containing
regimens, absence of ﬁxed-dose drug combinations, need
for refrigeration, and necessary meal restrictions. Finally,
thefearthatnofurthertreatmentoptionswillbeavailableif
subsequent failure on second-line regimens occurs might
also delay therapy switching [25].
In our study [26], more than half of the patientswere put
on NFV-based regimens, due to a lack of refrigeration
systems and heat-stable boosted protease inhibitors,
which are less effective than a regimen containing a
ritonavir-boosted protease inhibitor. Also, the choices
for replacing the NRTI drugs were limited due to a
restricted formulary of drugs. Despite these constraints,
our results showed that rescue following the failure of
WHO-recommendedﬁrst-linetreatment(including the
regimen d4T/3TC/NVP) is feasible and efﬁcient in
RLS,atleastinMSFprogrammes.Therefore,inaddition
to improving the diagnosis of treatment failure, the
obstacles to second-line drug access and usage must be
addressed by reducing costs, increasing the availabilityof
newer, more potent molecules (including heat-stable
formulations of boosted protease inhibitors), and
facilitating adherence through ﬁxed-dose formulations
that do not require food restrictions.
Less than 2% of patients eligible for the study were
excluded from the analyses because of unknown age, and
this percentage was similar across continents. We
recognize, however, several limitations in our study. First,
it was based on monitoring data from a multicentric
observational cohort, and the reason for switch to second
line was not recorded prospectively. Therefore, we cannot
completely exclude that some of the switches in therapy
wereinfactantiretroviraldrugreplacementsduetoreasons
other than treatment failure, such as drug toxicity. We are,
however,conﬁdentthatthemajorityofpatientseligiblefor
thisanalysisweretruetreatmentfailures,as62%hadatleast
one of the WHO criteria for treatment failure recorded,
andourdeﬁnition ofsecond-linetherapy (changesofboth
antiretroviral drug class and NRTI drug after more than
6 months of NNRTI therapy) is likely to have excluded
most of the patients with antiretroviral drug replacements
due to toxicity in the MSF context. Data on CD4 cell
counts were not collected for the remaining patients.
Second, clinico-immunological failure can occur in the
presence of virological control [5], and, although clinical
and immunological failure was conﬁrmed by a viral load




and immunological outcomes, the absence of viral load
measurements did not allow exclusion of suboptimal
virological suppression that would lead to less satisfactory
long-term outcomes. Finally, as we have included ART-
naive patients in the analysis, the outcomes cannot be
extrapolated topatientswho might have received ﬁrst-line
regimens prior to entry in the MSF cohort.
Unsurprisingly, we showed that severe immunosuppres-
sion at baseline for ﬁrst-line ART, and the history of a
severe clinical event (WHO stage 3 or 4), increased the
risk of mortality on second-line treatment. Our ﬁndings
thus stress the need to enable access to ﬁrst-line ART
before severe immunosuppression has developed, rein-
forcing the need to scale up early access to HIV testing
and treatment for those in RLS.
In summary, we report a relatively low rate of switch to
second-line HIV treatment in ART-naive adults in MSF
programmesinRLS,butgoodearlyoutcomesonsecond-
line therapy. Severe immunosuppression at ﬁrst-line ART
initiation increased mortality on second-line treatment.
Considering the success of patients put on a second-line
regimen, improving the tools to efﬁciently diagnose ﬁrst-
line treatment failure, and clearing the hurdles of access
and adherence to more effective drug regimens, are
criticalactionsthatshouldbetakentoallowmorepatients
in RLS to beneﬁt from second-line HIV therapy.
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